ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) Full Year 2024 Results
Key Financial Results
- Revenue: CN¥79.5m (up by CN¥71.8m from FY 2023).
- Net loss: CN¥315.9m (loss narrowed by 17% from FY 2023).
- CN¥0.84 loss per share (improved from CN¥1.05 loss in FY 2023).
1541 Products In Clinical Trials
- Phase I: 12.
- Phase III: 2.
All figures shown in the chart above are for the trailing 12 month (TTM) period
The primary driver behind last 12 months revenue was the United States of America segment contributing a total revenue of CN¥74.0m (93% of total revenue). The largest operating expense was Research & Development (R&D) costs, amounting to CN¥322.8m (82% of total expenses). Explore how 1541’s revenue and expenses shape its earnings.
ImmuneOnco…
